A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
The current price of AstraZeneca PLC in the market is 14Β 767,63Β β½, with a 24-hour trading volume of 186,02MΒ β½. The asset's market cap is 22,9TΒ β½, after moving -2.92% in the last day.
Tokenized AstraZeneca PLC is trading at 7Β 429,04Β β½, with a tokenized market cap of 55,71MΒ β½ and a 24-hour trading volume of 53,2MΒ β½. The tokenized asset has moved -3.36% in the past 24 hours.